252 related articles for article (PubMed ID: 36405011)
21. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract][Full Text] [Related]
22. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.
Sun L; Liu Z; Wu Z; Ning K; Hu J; Chen Z; Wu Z; Yin X
Front Immunol; 2023; 14():1113455. PubMed ID: 37051238
[TBL] [Abstract][Full Text] [Related]
24. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.
Wu Z; Guo L; Wan L; Xu K; Luo L; Wen Z
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11891-11905. PubMed ID: 37410140
[TBL] [Abstract][Full Text] [Related]
26. LMNB2 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Kong W; Wu Z; Yang M; Zuo X; Yin G; Chen W
IUBMB Life; 2020 Dec; 72(12):2672-2685. PubMed ID: 33211382
[TBL] [Abstract][Full Text] [Related]
27. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma.
Zhang BH; Yang J; Jiang L; Lyu T; Kong LX; Tan YF; Li B; Zhu YF; Xi AY; Xu X; Yan LN; Yang JY
Genomics; 2020 Jul; 112(4):2763-2771. PubMed ID: 32198063
[TBL] [Abstract][Full Text] [Related]
29. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
30. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
31. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
32. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
33. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
Guan R; Zou J; Mei J; Deng M; Guo R
BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
35. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
Front Immunol; 2022; 13():843408. PubMed ID: 35693827
[TBL] [Abstract][Full Text] [Related]
39. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
Wang Y; Wan X; Du S
Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics analysis and experimental validation of a novel autophagy-related signature relevant to immune infiltration for recurrence prediction after curative hepatectomy.
Wang H; Yang C; Li D; Wang R; Li Y; Lv L
Aging (Albany NY); 2023 Apr; 15(7):2610-2630. PubMed ID: 37014321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
